Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: A pilot randomized controlled trial

Luigi Taranto-Montemurro, Scott Sands, Ali Azarbarzin, Nicole Calianese, Daniel Vena, Lauren Hess, Sang-Wook Kim, David P White, Andrew Wellman, Luigi Taranto-Montemurro, Scott Sands, Ali Azarbarzin, Nicole Calianese, Daniel Vena, Lauren Hess, Sang-Wook Kim, David P White, Andrew Wellman

Abstract

Background and objective: Animal studies indicate that alpha-1 adrenergic receptor agonists and antimuscarinic agents improve genioglossus muscle activity during sleep and may be candidates for the pharmacological treatment of OSA. On the other hand, noradrenergic stimulants may be wake-promoting or cause insomnia symptoms if taken before bedtime, and the addition of a medication with sedative properties, such as an antihistaminic, may reduce these side effects. In this study, we aimed to determine the effects of the combination of an alpha-1 adrenergic agonist (pseudoephedrine) and an antihistaminic-antimuscarinic (diphenhydramine) on OSA severity (AHI), genioglossus responsiveness and other endotypic traits (Vpassive , muscle compensation, LG and arousal threshold).

Methods: Ten OSA patients performed a randomized, placebo-controlled, double-blind, crossover trial comparing one night of pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D) to placebo administered prior to sleep. The AHI, genioglossus muscle responsiveness to negative oesophageal pressure and the endotypic traits were measured via PSG.

Results: The participants' median (interquartile range) age was 50 (46-53) years and body mass index (BMI) was 34.3 (30.6-39.2) kg/m2 . The drug combination had no effect on AHI (21.6 (9.1-49.8) on placebo vs 37.9 (5.1-55.4) events/h on DAW1033D, P > 0.5) or genioglossus responsiveness (6.0 (2.6-9.2) on placebo vs 4.0 (3.5-7.3) %/cm H2 O). Amongst the phenotypic traits, only Vpassive was improved by 29 (3-55) % eupnoea, P = 0.03 (mean (95% CI)).

Conclusion: The combination of pseudoephedrine and diphenhydramine did not improve OSA severity or genioglossus responsiveness but induced a small improvement in upper airway collapsibility, possibly due to the decongestant effect of the medications. The results of this study do not support the use of these medications for OSA treatment.

Trial registration: ClinicalTrials.gov NCT03383887.

Keywords: combination therapy; decongestant in obstructive sleep apnoea; diphenhydramine; flu and cold; obstructive sleep apnoea; pharmacotherapy; pseudoephedrine.

© 2021 Asian Pacific Society of Respirology.

References

REFERENCES

    1. White DP, Younes MK. Obstructive sleep apnea. Compr. Physiol. 2012; 2: 2541-94.
    1. Horner RL. Motor control of the pharyngeal musculature and implications for the pathogenesis of obstructive sleep apnea. Sleep 1996; 19: 827-53.
    1. Horner RL, Hughes SW, Malhotra A. State-dependent and reflex drives to the upper airway: basic physiology with clinical implications. J. Appl. Physiol. 2014; 116: 325-36.
    1. Chan E, Steenland HW, Liu H, Horner RL. Endogenous excitatory drive modulating respiratory muscle activity across sleep-wake states. Am. J. Respir. Crit. Care Med. 2006; 174: 1264-73.
    1. Grace KP, Hughes SW, Horner RL. Identification of the mechanism mediating genioglossus muscle suppression in REM sleep. Am. J. Respir. Crit. Care Med. 2013; 187: 311-9.
    1. Taranto-Montemurro L, Edwards BA, Sands SA, Marques M, Eckert DJ, White DP, Wellman A. Desipramine increases genioglossus activity and reduces upper airway collapsibility during non-REM sleep in healthy subjects. Am. J. Respir. Crit. Care Med. 2016; 194: 878-85.
    1. Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. a randomized, placebo-controlled, double-blind crossover trial. Am. J. Respir. Crit. Care Med. 2019; 199: 1267-76.
    1. Taranto-Montemurro L, Sands SA, Edwards BA, Azarbarzin A, Marques M, de Melo C, Eckert DJ, White DP, Wellman A. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur. Respir. J. 2016; 48: 1340-50.
    1. Bart Sangal R, Sangal JM, Thorp K. Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness. Sleep Med. 2008; 9: 506-10.
    1. Brownell LG, West P, Sweatman P, Acres JC, Kryger MH. Protriptyline in obstructive sleep apnea: a double-blind trial. N. Engl. J. Med. 1982; 307: 1037-42.
    1. Conway WA, Zorick F, Piccione P, Roth T. Protriptyline in the treatment of sleep apnoea. Thorax 1982; 37: 49-53.
    1. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991; 100: 416-21.
    1. Bonora M, St John WM, Bledsoe TA. Differential elevation by protriptyline and depression by diazepam of upper airway respiratory motor activity. Am. Rev. Respir. Dis. 1985; 131: 41-5.
    1. Smith PL, Haponik EF, Allen RP, Bleecker ER. The effects of protriptyline in sleep-disordered breathing. Am. Rev. Respir. Dis. 1983; 127: 8-13.
    1. Whyte KF, Gould GA, Airlie MA, Shapiro CM, Douglas NJ. Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep 1988; 11: 463-72.
    1. Schweitzer P. Drugs that disturb sleep and wakefulness. In: Kryger MHRT, Dement WC (eds) Principles and Practice of Sleep Medicine, 5th edn. Elsevier, Philadelphia, PA, 2011; 542-60.
    1. Sands SA, Edwards BA, Terrill PI, Taranto-Montemurro L, Azarbarzin A, Marques M, Hess LB, White DP, Wellman A. Phenotyping pharyngeal pathophysiology using polysomnography in patients with obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2018; 197: 1187-97.
    1. Terrill PI, Edwards BA, Nemati S, Butler JP, Owens RL, Eckert DJ, White DP, Malhotra A, Wellman A, Sands SA. Quantifying the ventilatory control contribution to sleep apnoea using polysomnography. Eur. Respir. J. 2015; 45: 408-18.
    1. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am. J. Respir. Crit. Care Med. 2013; 188: 996-1004.
    1. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667-89.
    1. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF et al.; American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J. Clin. Sleep Med. 2012; 8: 597-619.
    1. Malhotra A, Trinder J, Fogel R, Stanchina M, Patel SR, Schory K, Kleverlaan D, White DP. Postural effects on pharyngeal protective reflex mechanisms. Sleep 2004; 27: 1105-12.
    1. Taranto-Montemurro L, Sands SA, Azarbarzin A, Marques M, de Melo CM, Edwards BA, Eckert DJ, Messineo L, White DP, Wellman A. Effect of 4-aminopyridine on genioglossus muscle activity during sleep in healthy adults. Ann. Am. Thorac. Soc. 2017; 14: 1177-83.
    1. Berry RB, Yamaura EM, Gill K, Reist C. Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 1999; 22: 1087-92.
    1. Sands SA, Terrill PI, Edwards BA, Taranto Montemurro L, Azarbarzin A, Marques M, de Melo CM, Loring SH, Butler JP, White D. Quantifying the arousal threshold using polysomnography in obstructive sleep apnea. Sleep 2018; 41: zsx183.
    1. Taranto-Montemurro L, Messineo L, Azarbarzin A, Vena D, Hess L, Calianese N, White D, Wellman A, Sands S. Effects of the combination of atomoxetine and oxybutynin on obstructive sleep apnea endotypic traits. Chest 2020; 157: 1626-36.
    1. Wellman A, Edwards BA, Sands SA, Owens RL, Nemati S, Butler J, Passaglia CL, Jackson AC, Malhotra A, White DP. A simplified method for determining phenotypic traits in patients with obstructive sleep apnea. J. Appl. Physiol. (1985) 2013; 114: 911-22.
    1. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 2005; 44: 571-90.
    1. Foley KF, Van Dort ME, Sievert MK, Ruoho AE, Cozzi NV. Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J. Neural Transm. (Vienna) 2002; 109: 1229-40.
    1. Fenik VB. Revisiting antagonist effects in hypoglossal nucleus: brainstem circuit for the state-dependent control of hypoglossal motoneurons: a hypothesis. Front. Neurol. 2015; 6: 254.
    1. Taranto-Montemurro L, Messineo L, Wellman A. Targeting endotypic traits with medications for the pharmacological treatment of obstructive sleep apnea. A review of the current literature. J. Clin. Med. 2019; 8: 1846.
    1. Paulsen FP, Steven P, Tsokos M, Jungmann K, Muller A, Verse T, Pirsig W. Upper airway epithelial structural changes in obstructive sleep-disordered breathing. Am. J. Respir. Crit. Care Med. 2002; 166: 501-9.
    1. Sekosan M, Zakkar M, Wenig BL, Olopade CO, Rubinstein I. Inflammation in the uvula mucosa of patients with obstructive sleep apnea. Laryngoscope 1996; 106: 1018-20.
    1. Vicente E, Marin JM, Carrizo SJ, Osuna CS, Gonzalez R, Marin-Oto M, Forner M, Vicente P, Cubero P, Gil AV et al. Upper airway and systemic inflammation in obstructive sleep apnoea. Eur. Respir. J. 2016; 48: 1108-17.
    1. Wasicko MJ, Hutt DA, Parisi RA, Neubauer JA, Mezrich R, Edelman NH. The role of vascular tone in the control of upper airway collapsibility. Am. Rev. Respir. Dis. 1990; 141: 1569-77.
    1. Wasicko MJ, Leiter JC, Erlichman JS, Strobel RJ, Bartlett D Jr. Nasal and pharyngeal resistance after topical mucosal vasoconstriction in normal humans. Am. Rev. Respir. Dis. 1991; 144: 1048-52.
    1. Bastedo T, Chan E, Park E, Liu H, Horner RL. Modulation of genioglossus muscle activity across sleep-wake states by histamine at the hypoglossal motor pool. Sleep 2009; 32: 1313-24.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever